Bavarian Nordic wins FDA OK for chikungunya vaccine in challenge to Valneva
The FDA has approved Bavarian Nordic’s chikungunya vaccine for adolescents and adults, edging out Valneva’s vaccine, which is only approved in people at least 18 years old. Bavarian’s single-dose asset, dubbed Vimkunya, is the first ...
The FDA has approved Bavarian Nordic’s chikungunya vaccine for adolescents and adults, edging out Valneva’s vaccine, which is only approved in people at least 18 years old.
Bavarian’s single-dose asset, dubbed Vimkunya, is the first ...
